Details of the Drug Combination

General Information of Drug Combination (ID: DC4P7OP)

• Drug Combination Name: BHV-0223 + Cisatracurium
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  BHV-0223 (DMBLM5H): N.A.
  Cisatracurium (DMUZPJ5): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 9.5
  Bliss Independence Score: 9.5
  Loewe Additivity Score: 23.76
  LHighest Single Agent (HSA) Score: 23.76

Molecular Interaction Atlas of This Drug Combination

Indication(s) of BHV-0223

Disease Entry	ICD 11	Status	REF
Amyotrophic lateral sclerosis	8B60.0	Phase 1	[2]

Indication(s) of Cisatracurium

Disease Entry	ICD 11	Status	REF
Muscle spasm	MB47.3	Approved	[3]

Cisatracurium Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Cholinergic receptor unspecific (CHR)	TTUPDWN	NOUNIPROTAC	Antagonist	[4]
Neuronal acetylcholine receptor alpha-2 (CHRNA2)	TTF4E0J	ACHA2_HUMAN	Antagonist	[5]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92.
• [5] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.